Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

GPCR

Structure Therapeutics Inc ADR

Last Close
Jun 25 • 04:00PM ET
39.96
Dollar change
-3.72
Percentage change
-8.52 		%
Scroll to Statements
Index- P/E- EPS (ttm)-2.31 Insider Own10.24% Shs Outstand46.41M Perf Week-17.74%
Market Cap1.86B Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float41.85M Perf Month4.28%
Income-97.56M PEG- EPS next Q-0.23 Inst Own85.89% Short Float9.97% Perf Quarter-7.52%
Sales0.00M P/S- EPS this Y-13.58% Inst Trans- Short Ratio4.39 Perf Half Y21.09%
Book/sh9.22 P/B4.33 EPS next Y21.89% ROA-27.69% Short Interest4.17M Perf Year36.29%
Cash/sh9.36 P/C4.27 EPS next 5Y- ROE-29.29% 52W Range25.57 - 75.02 Perf YTD-1.96%
Dividend Est.- P/FCF- EPS past 5Y- ROI-22.51% 52W High-46.73% Beta-3.70
Dividend TTM- Quick Ratio19.05 Sales past 5Y0.00% Gross Margin- 52W Low56.28% ATR (14)3.78
Dividend Ex-Date- Current Ratio19.05 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)39.36 Volatility6.38% 11.58%
Employees93 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price83.10
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q25.68% Payout- Rel Volume2.30 Prev Close43.68
Sales Surprise- EPS Surprise0.72% Sales Q/Q- EarningsMay 09 AMC Avg Volume950.12K Price39.96
SMA20-14.73% SMA50-3.15% SMA200-13.00% Trades Volume2,186,403 Change-8.52%
Date Action Analyst Rating Change Price Target Change
May-21-24Initiated JP Morgan Overweight $65
Apr-09-24Initiated Cantor Fitzgerald Overweight $65
Oct-19-23Initiated JMP Securities Mkt Outperform $90
Jul-27-23Initiated Piper Sandler Overweight $58
May-25-23Resumed Jefferies Buy $34 → $41
Feb-28-23Initiated SVB Securities Outperform $33
Feb-28-23Initiated Jefferies Buy $34
Feb-28-23Initiated Guggenheim Buy $50
Feb-28-23Initiated BMO Capital Markets Outperform $40
Jun-17-24 09:53AM
Could Structure Therapeutics Become the Next Novo Nordisk?
(Motley Fool)
Jun-11-24 07:31PM
Structure Therapeutics CEO on GLP drugs
(CNBC TV) -5.42%
09:59AM
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
(Zacks)
04:57AM
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
(Motley Fool)
Jun-09-24 07:30AM
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
(Motley Fool)
04:05PM Loading…
Jun-07-24 04:05PM
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
(GlobeNewswire)
05:00AM
Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundup
(Quartz)
Jun-05-24 07:53PM
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
(GlobeNewswire)
Jun-04-24 11:59AM
Qiming's Nisa Leung Made the 2024 Forbes Midas List
(PR Newswire)
06:00AM
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
(InvestorPlace)
02:03AM
Heard on the Street Monday Recap: Catnip
(The Wall Street Journal)
Jun-03-24 06:55PM
Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz
(CNBC TV) +54.21%
04:09PM
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
(GlobeNewswire)
03:30PM
Structure Therapeutics (GPCR) Stock Soars 60% on Weight Loss Drug Success
(InvestorPlace)
01:42PM
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
(Investor's Business Daily)
01:17PM Loading…
01:17PM
The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial results
(Quartz)
12:30PM
Heard on the Street: Wall Street Is Cheering a New Obesity Pill Candidate. Here's Why.
(The Wall Street Journal)
11:30AM
Structure Therapeutics Stock Soars on Obesity Pill Data
(The Wall Street Journal)
08:20AM
Structure pill leads to competitive weight loss in obesity study
(BioPharma Dive)
07:30AM
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
(GlobeNewswire)
Jun-02-24 09:07AM
J.P. Morgan Predicts up to 210% Gains for These 2 Strong Buy Stocks
(TipRanks)
May-31-24 06:00AM
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
(InvestorPlace)
May-21-24 07:44AM
JPMorgan Starts Structure Therapeutics With Overweight Rating
(MT Newswires)
May-09-24 10:56PM
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
(InvestorPlace) -7.32%
04:05PM
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
(GlobeNewswire)
10:34AM
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
(InvestorPlace)
Apr-24-24 06:33AM
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
(InvestorPlace)
Mar-30-24 09:37AM
7 Small-Cap Stocks that Wall Street Loves for Good Reason
(InvestorPlace)
Mar-15-24 10:53AM
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
Mar-08-24 04:05PM
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
(GlobeNewswire)
08:30AM Loading…
08:30AM
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
(GlobeNewswire)
Jan-22-24 05:24AM
Here's Why Structure Therapeutics (GPCR) Fell in Q4
(Insider Monkey)
Dec-25-23 07:45AM
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
(Motley Fool)
Dec-22-23 04:21PM
7 Small-Cap Stocks That Wall Street Loves for Good Reason
(InvestorPlace) +7.85%
Dec-18-23 04:06PM
Structure Plummets 43% After Trailing Lilly In Obesity Treatment
(Investor's Business Daily) -42.82% +10.05%
01:03PM
Another Drugmaker Hits Rocks Seeking a Weight-Loss Pill
(The Wall Street Journal)
11:29AM
New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.
(Barrons.com)
09:22AM
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader
(Investor's Business Daily)
07:30AM
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
(GlobeNewswire)
07:30AM
Structure Therapeutic obesity pill shows promise in mid-stage trial
(Reuters)
06:23AM
Structure shares sink as obesity pill misses expectations in small study
(BioPharma Dive)
Dec-11-23 12:26PM
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
(InvestorPlace)
Nov-29-23 02:28PM
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
(InvestorPlace)
02:30AM
11 Best Young Stocks to Buy and Hold For 20 Years
(Insider Monkey)
Nov-27-23 09:50AM
11 Best Upside Stocks To Buy Right Now
(Insider Monkey)
Nov-26-23 04:44PM
2 Biotech Stocks That Could Soar in December
(Motley Fool)
Nov-14-23 04:10PM
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire) -9.83%
Nov-03-23 05:20AM
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
(Motley Fool)
Oct-19-23 08:45AM
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
(PR Newswire)
Oct-06-23 08:45AM
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
(Zacks)
Oct-02-23 03:48PM
Why Shares of Structure Therapeutics Are Up Monday
(Motley Fool) +12.26%
Sep-29-23 04:04PM
Structure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity Treatment
(Investor's Business Daily) +34.56%
12:50PM
Why Shares of Structure Therapeutics Are Soaring on Friday
(Motley Fool)
11:19AM
Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo.
(Barrons.com)
10:24AM
Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results
(Bloomberg)
09:34AM
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
(Investor's Business Daily)
07:32AM
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
(GlobeNewswire)
07:30AM
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
(GlobeNewswire)
Aug-10-23 04:05PM
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire) -6.06%
Aug-03-23 05:32PM
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
(GlobeNewswire) -7.79%
Jul-16-23 07:00AM
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
(The Wall Street Journal)
Jun-27-23 02:10PM
Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills. What to Know.
(Barrons.com) +8.16%
01:35PM
Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know.
(Barrons.com)
08:12AM
Pfizer Makes a Call on Obesity Pill. Investors Arent Happy.
(Barrons.com)
Jun-26-23 09:05PM
Why Shares of Structure Therapeutics Rose Monday
(Motley Fool) +18.35%
Jun-16-23 08:00AM
This Biotech Is Developing The Next Ozempic. Should You Buy It?
(Motley Fool)
Jun-13-23 06:10AM
Institutional investors own a significant stake of 45% in Structure Therapeutics Inc. (NASDAQ:GPCR)
(Simply Wall St.)
Jun-12-23 10:15AM
Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years
(Motley Fool)
Jun-07-23 08:30AM
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
(GlobeNewswire)
May-31-23 04:30PM
Structure Therapeutics to Present at Jefferies Healthcare Conference
(GlobeNewswire)
May-25-23 04:30PM
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
(GlobeNewswire) +7.94% +9.97%
May-18-23 04:30PM
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
(GlobeNewswire) +7.64%
May-11-23 04:30PM
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire) +5.60%
May-03-23 06:59AM
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
(Simply Wall St.)
Mar-30-23 04:30PM
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
(GlobeNewswire) +7.65%
Feb-07-23 04:00PM
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares
(GlobeNewswire)
Feb-06-23 03:17PM
The Funded: A solar industry company is on deck to complete the 1st major Bay Area tech IPO in more than a year
(American City Business Journals)
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 12 '24Option Exercise0.42150,00063,000793,346Jun 14 08:19 PM
Lin XichenCHIEF SCIENTIFIC OFFICERJun 03 '24Option Exercise0.34106,20036,108191,907Jun 05 07:38 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.